Blackwell Kimberly
- SEC CIK
- 0001816465
No open-market purchases or sales filed in the past year.
Current role at each company
- GLUE Monte Rosa Therapeutics, Inc.Directoras of Jun 12, 2026
- IPSC Century Therapeutics, Inc.Directoras of Jun 12, 2026
- ZNTL Zentalis Pharmaceuticals, Inc.Chief Executive Officeras of Feb 5, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Blackwell Kimberly as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ZNTL Zentalis Pharmaceuticals, Inc.
Chief Executive Officer5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2023 (view filing) | Nov 13 | Same day | Blackwell KimberlyChief Executive Officer | PPurchase | +5.00K | $10.29 | +$51.5K | +2.0%254.8K after | |
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Blackwell KimberlyDirector | SSale | −1.00K | $83.74 | −$83.7K | −16.7%5.00K after | |
| Dec 2, 2021 (view filing) | Dec 1 | 1 day | Blackwell KimberlyDirector | SSale | −1.00K | $81.84 | −$81.8K | −16.7%5.00K after | |
| Nov 2, 2021 (view filing) | Nov 1 | 1 day | Blackwell KimberlyDirector | SSale | −1.00K | $80.46 | −$80.5K | −16.7%5.00K after | |
| Oct 27, 2021 (view filing) | Oct 25 | 2 days | Blackwell KimberlyDirector | SSale | −1.00K | $77.59 | −$77.6K | −16.7%5.00K after |